When it comes to defeating cancer having the correct mindset is just as important as having the correct treatment. The reason having the correct mindset is just as important as having the correct treatment is because if a patient has hope, they will continue to have the will to live, thus allowing the treatment to work. However, should the patient lose all hope they will lose the will to live then the body will stop working with the treatment and the patient will die. The nationally peer-reviewed journal Oncotarget understands this full well, and they have made it their personal mission to spread this news throughout all doctor offices and hospitals. Learn more about Oncotarget at researchgate.net
Oncotarget recently interviewed Dr. Carmelo Nucero who specializes as an oncologist dealing with papillary thyroid carcinoma. Patients who suffer from papillary thyroid carcinoma know full too well the story of losing hope.
The cancer papillary thyroid carcinoma is widely known to eventually become resistant to the drug vemurafenib. This is because vemurafenib focuses on healing the mutated BRAF gene which is the cause of papillary thyroid carcinoma. Unfortunately, the body often sees vemurafenib as a foreign attacker and mounts a defense against it. Once papillary thyroid carcinoma goes into remission the body continues to develop a resistance against vemurafenib so if the cancer comes back (which is often the case) the drug will no longer work. Download output styles at Endnote.com
Dr. Carmelo Nucero has made it his life mission to stop this awful cancer from continuing to spread, and he believes he may have found a solution.
— Oncotarget (@OncotargetJrnl) December 12, 2017
Because the body saw vemurafenib as a disease to be attacked the body had to be tricked into believing it was a domestic substance. In order to do that, Dr. Carmelo Nucero began mixing vemurafenib with other drugs. He found that if he mixed vemurafenib with the advanced breast cancer medication palbociclib than the body would attack palbociclib rather than vemurafenib thus allowing the medicine to work. He is hoping the FDA will prove treatment soon since both drugs are already approved.
For updates on this story and more listen to Oncotarget’s podcast on iTunes.